keyword
MENU ▼
Read by QxMD icon Read
search

Locally advanced prostate cancer

keyword
https://www.readbyqxmd.com/read/28734596/developments-in-urologic-oncology-%C3%A2-oncoforum%C3%A2-the-best-of-2016
#1
F Gómez-Veiga, A Alcaraz-Asensio, J Burgos-Revilla, J M Cózar-Olmo
OBJECTIVE: To put forth new findings of urologic oncology with impact on clinical practice presented during 2016 in the main annual meetings. ACQUISITION OF EVIDENCE: This document reviews abstracts on prostate, kidney and bladder cancer presented at the congresses of 2016 (EAU, AUA, ASCO, ESMO and ASTRO) and publications with the highest impact in this period valued with the highest scores by the OncoForum committee. SYNTHESIS OF EVIDENCE: In High-Risk Renal-Cell carcinoma after nephrectomy, disease-free survival was significantly greater for sunitinib than placebo group, with adverse events more frequents...
July 19, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28725597/canine-prostate-models-in-preclinical-studies-of-minimally-invasive-interventions-part-i-canine-prostate-anatomy-and-prostate-cancer-models
#2
REVIEW
Fei Sun, Claudia Báez-Díaz, Francisco Miguel Sánchez-Margallo
The high prevalence of prostate cancer (PCa) in elderly men and technical advances in early detection of localized PCa have led to continued efforts to develop new therapeutic options of minimally invasive nature in current urologic oncology community. Increasing newly emerging therapies are undergoing preclinical tests on the technical feasibility, efficacy and safety in animal experiments. The dog is an ideal large animal because of its similar anatomy to human and the capability allowing the use of the same medical devices applied in future clinical trials...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725591/diffusion-weighted-imaging-of-the-prostate-principles-application-and-advances
#3
REVIEW
Martin H Maurer, Johannes T Heverhagen
This review article aims to provide an overview on the principles of diffusion-weighted magnetic resonance imaging (DW-MRI) and its applications in the imaging of the prostate. DW-MRI with regards to different applications for prostate cancer (PCa) detection and characterization, local staging as well as for active surveillance (AS) and tumor recurrence after radical prostatectomy (RP) will be discussed. Furthermore, advances in DW-MRI techniques like diffusion kurtosis imaging (DKI) will be presented.
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725590/mri-fusion-biopsy-the-contemporary-experience
#4
REVIEW
Marc A Bjurlin, Andrew B Rosenkrantz, Samir S Taneja
Advancements in magnetic resonance imaging (MRI) and MRI-ultrasound (US)-fusion targeted biopsy have resulted in a paradigm shift in the diagnosis of prostate cancer by overcoming the limitations of systematic biopsy. Prebiopsy MRI and MRI-US-fusion biopsy results in an increased detection of clinically significant disease, reduction in the detection of indolent disease, and allows for tumor localization during targeted biopsy. With these advantages, we have adopted a prebiopsy MRI and MRI-US-fusion biopsy diagnostic care pathway for all men at risk for prostate cancer and have performed more than 1900 biopsies to date...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725579/multiparametric-magnetic-resonance-imaging-of-the-prostate-a-basic-tutorial
#5
REVIEW
Miguel C Cabarrus, Antonio C Westphalen
Prostate cancer is the second most common cause of cancer related death in the United States and the most commonly diagnosed malignancy in men. In general, prostate cancer is slow growing, though there is a broad spectrum of disease that may be indolent, or aggressive and rapidly progressive. Screening for prostate is controversial and complicated by lack of specificity and over diagnosis of clinically insignificant cancer. Imaging has played a role in diagnosis of prostate cancer, primarily through systemic transrectal ultrasound (TRUS) guided biopsy...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28723656/inhibitor-of-h3k27-demethylase-jmjd3-utx-gsk-j4-is-a-potential-therapeutic-option-for-castration-resistant-prostate-cancer
#6
Viacheslav M Morozov, Ying Li, Matthew M Clowers, Alexander M Ishov
Androgen receptor (AR) mediates initiation and progression of prostate cancer (PCa); AR-driven transcription is activated by binding of androgens to the ligand-binding domain (LBD) of AR. Androgen ablation therapy offers only a temporary relief of locally advanced and metastatic PCa, and the disease eventually recurs as a lethal castration-resistant PCa (CRPC) as there is no effective treatment for CRPC patients. Thus, it is critical to identify novel targeted and combinatorial regimens for clinical management of CRPC...
July 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28723512/palliative-radical-cysto-prostatectomy-for-locally-advanced-symptomatic-castration-resistant-prostate-cancer
#7
Axel Heidenreich
Palliative radical (cysto-)prostatectomy is associated with a median symptom-free survival which covers 75-80% of the remaining lifetime in patients with symptomatic locally advanced castration-resistant prostate cancer.
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28722437/surface-plasmon-resonance-clinical-biosensors-for-medical-diagnostics
#8
Jean-Francois Masson
The design and application of sensors for monitoring biomolecules in clinical samples is a common goal of the sensing research community. Surface plasmon resonance (SPR) and other plasmonic techniques such as localized surface plasmon resonance (LSPR) and imaging SPR are reaching a maturity level sufficient for their application in monitoring biomolecules in clinical samples. In recent years, the first examples for monitoring antibodies, proteins, enzymes, drugs, small molecules, peptides, and nucleic acids in biofluids collected from patients afflicted with a series of medical conditions (Alzheimer's, hepatitis, diabetes, leukemia, and cancers such as prostate and breast cancers, among others) demonstrate the progress of SPR sensing in clinical chemistry...
January 27, 2017: ACS Sensors
https://www.readbyqxmd.com/read/28721912/exosomes-and-exosomal-micrornas-in-prostate-cancer-radiation-therapy
#9
REVIEW
Bijaya Malla, Kathrin Zaugg, Erik Vassella, Daniel M Aebersold, Alan Dal Pra
Despite current risk stratification systems using traditional clinicopathologic factors, many localized and locally advanced prostate cancers fail radical treatment (ie, radical prostatectomy, radiation therapy with or without androgen deprivation therapy). Therefore, a pressing need exists for enhanced methods of disease stratification through novel prognostic and predictive tools that can reliably be applied in clinical practice. Exosomes are 50- to 150-nm small vesicles released by cancer cells that reflect the genetic and nongenetic materials of parent cancer cells...
August 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28712484/relevance-of-dna-damage-repair-in-the-management-of-prostate-cancer
#10
Patricia Banks, Wen Xu, Declan Murphy, Paul James, Shahneen Sandhu
Recent insights into the genomic aberrations that underlie and drive prostate cancer have redoubled efforts to molecularly stratify treatments based on predictive markers. Approximately 23% of patients with metastatic castration-resistant prostate cancer exhibit somatic or germline aberrations in genes implicated in DNA repair, such as BRCA2, BRCA1, ATM, CHEK2, and PALB2, as well as mismatch repair genes. At least 10% of men with advanced disease have germline mutations in DNA-repair genes (DRG). The enrichment of DRG defects in metastatic disease compared with localized, primary tumors suggests a possible role in carcinogenesis, disease progression, and potentially accounts for a more aggressive phenotype...
June 27, 2017: Current Problems in Cancer
https://www.readbyqxmd.com/read/28707842/leisure-time-physical-activity-and-risk-of-prostate-cancer-a-dose-response-meta-analysis
#11
Feng Liu, Jing Wang, Hai-Long Wu, Hui Wang, Jian-Xiang Wang, Rui Zhou, Zhi Zhu
INTRODUCTION: Physical activity (PA) may be a protect factor against prostate cancer (Pca). We aim to investigate and establish the potential relationship between leisure-time PA and Pca. EVIDENCE ACQUISITION: PubMed, Embase databases were searched for eligibly studies (cohort) before Aug-11, 2016. We conducted a meta-analysis to pool the dose-specific effects between leisure-time PA and Pca. Subgroup analysis was employed to see the potential variation among each group...
July 12, 2017: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/28699539/recent-advances-in-the-function-of-the-67-kda-laminin-receptor-and-its-targeting-for-personalized-therapy-in-cancer
#12
Ada Pesapane, Pia Ragno, Carmine Selleri, Nunzia Montuori
The 67 kDa high affinity laminin receptor (67LR) is a non integrin cell surface receptor for laminin, the major component of basement membranes. Interactions between 67LR and laminin play a major role in mediating cell adhesion, migration, proliferation and survival. 67LR derives from homo- or hetero-dimerization of a 37 kDa cytosolic precursor (37LRP), most probably by fatty acid acylation. Interestingly, 37LRP, also called p40 or OFA/iLR (oncofetal antigen/immature laminin receptor), is a multifunctional protein with a dual activity in the cytoplasm and in the nucleus...
July 10, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28692047/androgen-induces-g3bp2-and-sumo-mediated-p53-nuclear-export-in-prostate-cancer
#13
D Ashikari, K Takayama, T Tanaka, Y Suzuki, D Obinata, T Fujimura, T Urano, S Takahashi, S Inoue
The androgen receptor (AR) has a central role in prostate cancer progression, particularly treatment-resistance disease including castration-resistant prostate cancer. Loss of the p53 tumor suppressor, a nuclear transcription factor, is also known to contribute to prostate malignancy. Here we report that p53 is translocated to the cytoplasm by androgen-mediated induction of G3BP2, a newly described direct target gene of AR. G3BP2 induces both cell cycle progression and blocks apoptosis. Translocation of p53 is regulated by androgen-dependent sumoylation mediated by the G3BP2-interacting SUMO-E3 ligase, RanBP2...
July 10, 2017: Oncogene
https://www.readbyqxmd.com/read/28691182/hsp70-inhibitors-suppress-androgen-receptor-expression-in-lncap95-prostate-cancer-cells
#14
Kazuaki Kita, Masayuki Shiota, Masako Tanaka, Asuka Otsuka, Masaki Matsumoto, Minoru Kato, Satoshi Tamada, Hiroshi Iwao, Katsuyuki Miura, Tatsuya Nakatani, Shuhei Tomita
Androgen deprivation therapy (ADT) is initially effective for treating patients with advanced prostate cancer; however, the prostate cancer gradually becomes resistant to ADT, which is termed castration-resistant prostate cancer (CRPC). Androgen receptor splice variant 7 (AR-V7), one of the causes of CRPC, is correlated with the resistance to a new-generation AR antagonist (enzalutamide) and poor prognosis. Heat shock protein 70 (Hsp70) inhibitor is known to decrease the levels of full-length AR (AR-FL), but little is known about its effects against CRPC cells expressing AR-V7...
July 10, 2017: Cancer Science
https://www.readbyqxmd.com/read/28687599/psma-ligands-for-pet-imaging-of-prostate-cancer
#15
Sarah M Schwarzenböck, Isabel Rauscher, Christina Bluemel, Wolfgang P Fendler, Steven P Rowe, Martin G Pomper, Ali Afshar-Oromieh, Ken Herrmann, Matthias Eiber
Targeting the prostate-specific membrane antigen (PSMA) with (68)Ga-labelled and (18)F-labelled PET-agents has become increasingly important in recent years. Imaging of biochemically recurrent prostate cancer (PC) has been established as a widely accepted clinical indication for PSMA ligand PET/CT in many parts of the world due to the results of multiple, primarily retrospective, studies that indicate superior detection efficacy compared to standard of care imaging. For high-risk primary PC, evidence is growing that this modality significantly aids in the detection of otherwise occult nodal and bone metastases...
July 7, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28687398/the-impact-of-comorbidities-on-the-benefits-of-prolonged-androgen-ablation-in-patients-with-t3-4-prostate-cancer-treated-with-external-beam-radiation-therapy
#16
Eric Tran, Matthew Paquette, Justin Jay, Jeremy Hamm, Mitchell Liu, Graeme Duncan, Tom Pickles, Scott Tyldesley
PURPOSE: To determine whether the survival benefit associated with prolonged androgen deprivation therapy (ADT) and radiotherapy (EBRT) varies with baseline estimates of overall survival in cT3-4 prostate cancer patients (PCa). METHODS AND MATERIALS: In 1997, the BC Cancer Agency adopted as standard a policy of prolonged ADT (>18months) with EBRT for locally advanced PCa. Two cohorts of cT3-T4 PCa treated with EBRT were selected: 1993-1995 (early: N=725) and 1999-2001 (late: N=584)...
July 4, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28683707/docetaxel-in-hormone-sensitive-advanced-prostate-cancer-genesis-sefh-evaluation-reporta
#17
Juan Carlos García de Paredes Esteban, Emilio Jesús Alegre Del Rey, Rocío Asensi Díez
Prostate cancer (PC) is the most common urogenital malignancy in older men and the second leading cause of death by cancer in men in Europe. Current therapeutic practice considers Androgen Deprivation Therapy (ADT) as first line treatment for clinically localized prostate cancer at high-risk, either locally advanced or metastatic. ADT can be achieved through orchiectomy (surgical castration), luteinizing hormone-releasing hormone (LHRH) agonists, or through complete androgen blockade (LHRH agonist combined with an anti-androgen)...
July 1, 2017: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/28676102/effects-of-an-interactive-mhealth-innovation-for-early-detection-of-patient-reported-symptom-distress-with-focus-on-participatory-care-protocol-for-a-study-based-on-prospective-randomised-controlled-trials-in-patients-with-prostate-and-breast-cancer
#18
Ann Langius-Eklöf, Marie-Therése Crafoord, Mats Christiansen, Maria Fjell, Kay Sundberg
BACKGROUND: Cancer patients are predominantly treated as out-patients and as they often experience difficult symptoms and side effects it is important to facilitate and improve patient-clinician communication to support symptom management and self-care. Although the number of projects within supportive cancer care evaluating mobile health is increasing, few evidence-based interventions are described in the literature and thus there is a need for good quality clinical studies with a randomised design and sufficient power to guide future implementations...
July 4, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28675891/the-role-of-radical-prostatectomy-and-radiotherapy-in-treatment-of-locally-advanced-prostate-cancer-a-systematic-review-and-meta-analysis
#19
Omar Fahmy, Mohd Ghani Khairul-Asri, Syed H S M Hadi, Georgios Gakis, Arnulf Stenzl
BACKGROUND: The role of radical prostatectomy (RP) is still controversial for locally advanced prostate cancer (PC). Radiotherapy (RT) and hormonal therapy (HT) are usually used as a primary treatment. MATERIAL AND METHODS: A systematic online search was conducted according to Preferred Reporting Items for Systematic Review and Meta-Analysis statement. Eligible publications reporting the overall survival (OS) and/or disease-specific survival (DSS) were included...
July 4, 2017: Urologia Internationalis
https://www.readbyqxmd.com/read/28667390/novel-psca-targeting-scfv-fusion-proteins-for-diagnosis-and-immunotherapy-of-prostate-cancer
#20
Claudia Kessler, Alessa Pardo, Mehmet K Tur, Stefan Gattenlöhner, Rainer Fischer, Katharina Kolberg, Stefan Barth
PURPOSE: Despite great progress in the diagnosis and treatment of localized prostate cancer (PCa), there remains a need for new diagnostic markers that can accurately distinguish indolent and aggressive variants. One promising approach is the antibody-based targeting of prostate stem cell antigen (PSCA), which is frequently overexpressed in PCa. Here, we show the construction of a molecular imaging probe comprising a humanized scFv fragment recognizing PSCA genetically fused to an engineered version of the human DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT), the SNAP-tag, enabling specific covalent coupling to various fluorophores for diagnosis of PCa...
June 30, 2017: Journal of Cancer Research and Clinical Oncology
keyword
keyword
3465
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"